İLKOPOL was founded specifically to manufacture high potent, non-sterile products.
İLKO PHARMACEUTICALS AND POLAR PHARMACEUTICALS
İLKOPOL is a joint subsidiary of İLKO Pharmaceuticals and Polar Pharmaceuticals. İLKOPOL operates with the scientific competence, experience, cutting-edge technology, and quality assurance of İLKO Pharmaceuticals and Polar Pharmaceuticals. İLKOPOL Production Facility has the GMP certificate of the Ministry of Health of the Republic of Turkey.
Polar Pharmaceuticals entered the pharmaceutical industry in 2013 and invested in a production facility with a closed area of 2,600 m2 designed in accordance with Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) rules. The facility has reached its current position with the partnership of İLKO Pharmaceuticals.
İLKO Pharmaceuticals aims to be a leading company amid global competition with all its production and R&D investments by utilizing the cutting-edge technologies required by modern medicine and offering innovative products that improve people’s quality of life and save lives.
İLKO Pharmaceuticals has a broad product portfolio covering all major treatment areas.
The company is also active in biotechnology and consumer health (Wellcare).
İLKO Pharmaceutical Production Plant, the largest pharmaceutical investment in Anatolia, began operating in 2012. Capable of manufacturing up to 120 million boxes, the Manufacturing Plant has Turkish Ministry of Health GMP, EU GMP, and Russian Health Authority GMP certificates.
İLKO Pharmaceuticals is focused on advanced technology, and it has the first and only manufacturing technology of its kind in Turkey. ‘Core-in Tablet Technology providing delayed release’ (Chronopharmaceutical Product) and MUPS (Multiple Unit Pellet System) are only available from İLKO Pharmaceuticals.
One of the top 10 companies in Türkiye in terms of R&D spending, İLKO Pharmaceuticals has two separate R&D Centers:
- Complementing our range of small molecule generic and Wellcare branded consumer health products, the İLKO Argem R&D Center, based in Hacettepe University Technopark, is committed to pioneering innovative solutions based on state-of-the-art technology.
- The İLKO Argem Biotechnology Center, Türkiye's first biotechnology R&D facility, continues to develop biotechnological drugs through the application of recombinant DNA technology.
İLKO Pharmaceuticals achieved a first in Türkiye in December, by taking steps to establish our country as a player in the biotechnology market, seen as the future of the pharmaceutical industry, and founding the İLKOGEN company in association with Genexine, a South Korean biotechnology company.
Breaking new ground in healthcare sector, İLKO PHARMACEUTICALS aims to pioneer the production of high potent non-sterile drugs -- rarely manufactured in Türkiye and difficult to develop -- with its investment in İLKOPOL.
Intended to provide CMO services to national and international pharmaceutical companies, İLKOPOL will manufacture the very high-tech products used in the treatment of Rare Diseases, Oncology, and DMART in addition to providing treatment support to all patients and physicians. It will also contribute to the national economy by domestically manufacturing these expensive products, most of which are currently imported.